This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Canon U.S.A. Enters Into Collaborative Research Agreements With Massachusetts General Hospital And Brigham And Women’s Hospital

Canon U.S.A., Inc., has entered into respective collaborative research agreements with Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH) to develop biomedical optical imaging and medical robotics technologies, among other initiatives. The overall goal of the agreements is to develop and commercialize unique medical devices for a variety of applications including detection of cardiovascular disease, brain functional imaging, robotics-assisted neurosurgery and miniature endoscopy. Canon U.S.A. is working in conjunction with its parent, Canon Inc., on this endeavor.

This collaboration involves technology experts from the MGH Wellman Center for Photomedicine, MGH Athinoula A. Martinos Center for Biomedical Imaging, MGH Pathology Imaging and Communication Technology (PICT) Center, BWH National Center for Image Guided Therapy and BWH Center for Image-based Phenotyping. Together with the support of research and development staff from Canon U.S.A. and Canon Inc., they will work towards a common vision of pairing optics with pioneering diagnosis.

“Canon is very excited to be collaborating with these world-class hospitals to help solve clinical challenges facing healthcare communities worldwide,” said Dr. Toshiaki Ikoma, executive vice president and chief technology officer, Canon Inc. “Canon is committed to enhancing our worldwide R&D efforts while emphasizing our medical imaging through the creation of the Healthcare Optics Research Laboratory in Boston. The mission of the new laboratory is to research, develop, and facilitate the commercialization of unique medical devices. While we are in the very early stages of our research, we look forward to a long affiliation with one another to help ensure the results of our clinical findings are implemented in the future.”

"These agreements are quite different from the usual academic-industrial agreements because we will be working together to bring new MGH- and BWH-invented technologies from their current, very early stage, through prototype and scale-up, to our ultimate goals of FDA approval and clinical adoption," noted Dr. Frances Toneguzzo, executive director of the Office of Research Ventures & Licensing that manages innovations developed at MGH and BWH. "Together the parties will be dedicated to developing this technology from its basic scientific principles all the way to initial prototyping within the biological research and clinical environments with the ultimate goal of bringing these products to the patient.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs